Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04975997
Registration number
NCT04975997
Ethics application status
Date submitted
2/07/2021
Date registered
26/07/2021
Date last updated
3/04/2026
Titles & IDs
Public title
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Query!
Scientific title
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Query!
Additional trial identifiers [1]
0
0
U1111-1260-2872
Query!
Additional trial identifiers [2]
0
0
CC-220-MM-002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
EXCALIBER-RRMM
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Multiple Myeloma
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Daratumumab
Treatment: Drugs - Bortezomib
Treatment: Drugs - Iberdomide
Treatment: Drugs - Iberdomide
Treatment: Drugs - Iberdomide
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Daratumumab
Experimental: Daratumumab in combination with Iberdomide and dexamethasone - Dose 1 - Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone.
Experimental: Daratumumab in combination with Iberdomide and dexamethasone - Dose 2 -
Experimental: Daratumumab in combination with Iberdomide and dexamethasone - Dose 3 -
Active comparator: Daratumumab in combination with dexamethasone and bortezomib - Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone
Treatment: Drugs: Dexamethasone
Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
Treatment: Drugs: Daratumumab
Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle
Treatment: Drugs: Bortezomib
Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
Treatment: Drugs: Iberdomide
Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
Treatment: Drugs: Iberdomide
Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
Treatment: Drugs: Iberdomide
Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
Treatment: Drugs: Dexamethasone
Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8
Treatment: Drugs: Daratumumab
Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [1]
0
0
To compare the efficacy of iberdomide (also known as BMS-986382), daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) in terms of progression free survival (PFS).
Query!
Timepoint [1]
0
0
Up to approximately 5 years
Query!
Primary outcome [2]
0
0
Minimal Residual Disease (MRD) negative Complete Response (CR) at any time
Query!
Assessment method [2]
0
0
To compare the efficacy of iberdomide (also known as BMS-986382), daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) in terms of minimal residual disease (MRD) negative complete response (CR) at any time.
Query!
Timepoint [2]
0
0
Up to approximately 5 years
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
To evaluate clinical efficacy in terms of overall survival (OS) in participants with relapsed or refractory multiple myeloma (RRMM) treated with iberdomide, daratumumab, and dexamethasone (IberDd) compared to daratumumab, bortezomib, and dexamethasone (DVd).
Query!
Timepoint [1]
0
0
Up to approximately 5 years
Query!
Secondary outcome [2]
0
0
Sustainability of Minimal Residual Disease (MRD) negativity
Query!
Assessment method [2]
0
0
To evaluate the sustainability of minimal residual disease (MRD) negativity.
Query!
Timepoint [2]
0
0
Up to approximately 5 years
Query!
Secondary outcome [3]
0
0
Overall Response Rate (ORR)
Query!
Assessment method [3]
0
0
Calculated as percentage of participants who achieve best response of partial response (PR) or better according to the IMWG Uniform Response Criteria for multiple myeloma.
Query!
Timepoint [3]
0
0
Up to approximately 5 years
Query!
Secondary outcome [4]
0
0
Time to response (TTR)
Query!
Assessment method [4]
0
0
Time from randomization to the first documentation of response (PR or better).
Query!
Timepoint [4]
0
0
Up to approximately 5 years
Query!
Secondary outcome [5]
0
0
Duration of Response (DoR)
Query!
Assessment method [5]
0
0
Time from the first documentation of response (PR or better) to the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first.
Query!
Timepoint [5]
0
0
Up to approximately 5 years
Query!
Secondary outcome [6]
0
0
Time to Progression (TTP)
Query!
Assessment method [6]
0
0
The time from randomization to the first documented disease progression.
Query!
Timepoint [6]
0
0
Up to approximately 5 years
Query!
Secondary outcome [7]
0
0
Time to Next Treatment (TTNT)
Query!
Assessment method [7]
0
0
Time from randomization to the start of the next antimyeloma treatment.
Query!
Timepoint [7]
0
0
Up to approximately 5 years
Query!
Secondary outcome [8]
0
0
Progression-free Survival 2 (PFS2)
Query!
Assessment method [8]
0
0
Time from randomization to progression on the next anti-myeloma treatment or death due to any cause, whichever occurs first.
Query!
Timepoint [8]
0
0
Up to approximately 5 years
Query!
Secondary outcome [9]
0
0
Safety
Query!
Assessment method [9]
0
0
Type, frequency, seriousness and severity of adverse events (AEs), and relationship of AEs to study treatment.
Query!
Timepoint [9]
0
0
Up to approximately 5 years
Query!
Secondary outcome [10]
0
0
European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30)
Query!
Assessment method [10]
0
0
Mean changes from baseline in subscale scores in subject-reported health related quality of life outcomes and multiple myeloma-related symptoms as measured by the EORTC QLQ-C30.
Query!
Timepoint [10]
0
0
Up to approximately 5 years
Query!
Secondary outcome [11]
0
0
European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20)
Query!
Assessment method [11]
0
0
EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Mean changes from baseline in subscale scores in subject-reported health related quality of life outcomes and multiple myeloma-related symptoms as measured by the EORTC QLQ- MY20.
Query!
Timepoint [11]
0
0
Up to approximately 5 years
Query!
Secondary outcome [12]
0
0
Recommended iberdomide dose for Stage 2
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Up to approximately 1 year
Query!
Secondary outcome [13]
0
0
Area under the plasma concentration-time curve from time zero to tau (AUC(TAU))
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Up to approximately 1 year
Query!
Secondary outcome [14]
0
0
Maximum plasma concentration (Cmax)
Query!
Assessment method [14]
0
0
Query!
Timepoint [14]
0
0
Up to approximately 1 year
Query!
Secondary outcome [15]
0
0
Time to maximum plasma concentration (Tmax)
Query!
Assessment method [15]
0
0
Query!
Timepoint [15]
0
0
Up to approximately 1 year
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria
* Documented diagnosis of multiple myeloma (MM) and measurable disease.
* Received 1 to 2 prior lines of anti-myeloma therapy.
* Must have documented disease progression during or after their last anti-myeloma regimen.
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
Exclusion Criteria
* Any condition that confounds the ability to interpret data from the study.
* Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis.
* Known central nervous system involvement with MM.
* Prior therapy with iberdomide.
* Other protocol-defined Inclusion/Exclusion criteria apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
23/06/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
25/06/2032
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
939
Query!
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Local Institution - 813 - Birtinya
Query!
Recruitment hospital [2]
0
0
Local Institution - 812 - Douglas
Query!
Recruitment hospital [3]
0
0
Local Institution - 803 - Adelaide
Query!
Recruitment hospital [4]
0
0
Local Institution - 806 - Bedford Park
Query!
Recruitment hospital [5]
0
0
Local Institution - 802 - Clayton
Query!
Recruitment hospital [6]
0
0
Local Institution - 809 - East Melbourne
Query!
Recruitment hospital [7]
0
0
Local Institution - 801 - Melbourne
Query!
Recruitment hospital [8]
0
0
Local Institution - 811 - Murdoch
Query!
Recruitment hospital [9]
0
0
Local Institution - 807 - West Perth
Query!
Recruitment hospital [10]
0
0
Local Institution - 804 - Camperdown
Query!
Recruitment hospital [11]
0
0
Local Institution - 800 - Fitzroy
Query!
Recruitment hospital [12]
0
0
Local Institution - 808 - Garran
Query!
Recruitment postcode(s) [1]
0
0
4575 - Birtinya
Query!
Recruitment postcode(s) [2]
0
0
4814 - Douglas
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [4]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [5]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [6]
0
0
3001 - East Melbourne
Query!
Recruitment postcode(s) [7]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [8]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [9]
0
0
6005 - West Perth
Query!
Recruitment postcode(s) [10]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [11]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [12]
0
0
ACT 2605 - Garran
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Minnesota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Montana
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New Jersey
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New York
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
North Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Ohio
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Oklahoma
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oregon
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Tennessee
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Texas
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Virginia
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Wisconsin
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Buenos Aires
Query!
Country [26]
0
0
Austria
Query!
State/province [26]
0
0
Graz
Query!
Country [27]
0
0
Austria
Query!
State/province [27]
0
0
Linz
Query!
Country [28]
0
0
Austria
Query!
State/province [28]
0
0
Salzburg
Query!
Country [29]
0
0
Austria
Query!
State/province [29]
0
0
Sankt Pölten
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Vienna
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Bruges
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Brussels
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Paraná
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
Rio Grande do Sul
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
São Paulo
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Rio de Janeiro
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Alberta
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
British Columbia
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
New Brunswick
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Newfoundland and Labrador
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Nova Scotia
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Quebec
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Saskatchewan
Query!
Country [44]
0
0
China
Query!
State/province [44]
0
0
Hunan
Query!
Country [45]
0
0
China
Query!
State/province [45]
0
0
Jiangxi
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Shaanxi
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Shanghai Municipality
Query!
Country [48]
0
0
China
Query!
State/province [48]
0
0
Shanxi
Query!
Country [49]
0
0
China
Query!
State/province [49]
0
0
Zhejiang
Query!
Country [50]
0
0
China
Query!
State/province [50]
0
0
Beijing
Query!
Country [51]
0
0
China
Query!
State/province [51]
0
0
Changchun
Query!
Country [52]
0
0
China
Query!
State/province [52]
0
0
Chaoyang District
Query!
Country [53]
0
0
China
Query!
State/province [53]
0
0
Guangzhou
Query!
Country [54]
0
0
China
Query!
State/province [54]
0
0
Hangzhou
Query!
Country [55]
0
0
China
Query!
State/province [55]
0
0
Hangzhou, Zhejiang
Query!
Country [56]
0
0
China
Query!
State/province [56]
0
0
Harbin
Query!
Country [57]
0
0
China
Query!
State/province [57]
0
0
Nanjing
Query!
Country [58]
0
0
China
Query!
State/province [58]
0
0
Shanghai
Query!
Country [59]
0
0
China
Query!
State/province [59]
0
0
Shenyang
Query!
Country [60]
0
0
China
Query!
State/province [60]
0
0
Suzhu
Query!
Country [61]
0
0
China
Query!
State/province [61]
0
0
Tianjin
Query!
Country [62]
0
0
China
Query!
State/province [62]
0
0
Wuhan
Query!
Country [63]
0
0
China
Query!
State/province [63]
0
0
Xi'an
Query!
Country [64]
0
0
China
Query!
State/province [64]
0
0
Zhengzhou
Query!
Country [65]
0
0
Czechia
Query!
State/province [65]
0
0
Brno
Query!
Country [66]
0
0
Czechia
Query!
State/province [66]
0
0
Ostrava-Poruba
Query!
Country [67]
0
0
Czechia
Query!
State/province [67]
0
0
Prague
Query!
Country [68]
0
0
Denmark
Query!
State/province [68]
0
0
Aalborg
Query!
Country [69]
0
0
Denmark
Query!
State/province [69]
0
0
Odense
Query!
Country [70]
0
0
Denmark
Query!
State/province [70]
0
0
Roskilde
Query!
Country [71]
0
0
Finland
Query!
State/province [71]
0
0
Southwest Finland
Query!
Country [72]
0
0
Finland
Query!
State/province [72]
0
0
Helsinki
Query!
Country [73]
0
0
Finland
Query!
State/province [73]
0
0
Oulu
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
Argenteuil
Query!
Country [75]
0
0
France
Query!
State/province [75]
0
0
La Roche-sur-Yon
Query!
Country [76]
0
0
France
Query!
State/province [76]
0
0
Lille
Query!
Country [77]
0
0
France
Query!
State/province [77]
0
0
Nancy
Query!
Country [78]
0
0
France
Query!
State/province [78]
0
0
Nantes
Query!
Country [79]
0
0
France
Query!
State/province [79]
0
0
Paris
Query!
Country [80]
0
0
France
Query!
State/province [80]
0
0
Pessac
Query!
Country [81]
0
0
France
Query!
State/province [81]
0
0
Rouen
Query!
Country [82]
0
0
France
Query!
State/province [82]
0
0
Toulouse
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Schleswig-Holstein
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Frankfurt am Main
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Hamburg
Query!
Country [86]
0
0
Germany
Query!
State/province [86]
0
0
Heidelberg
Query!
Country [87]
0
0
Germany
Query!
State/province [87]
0
0
Lübeck
Query!
Country [88]
0
0
Greece
Query!
State/province [88]
0
0
Achaea
Query!
Country [89]
0
0
Greece
Query!
State/province [89]
0
0
Achaia
Query!
Country [90]
0
0
Greece
Query!
State/province [90]
0
0
Athens
Query!
Country [91]
0
0
Greece
Query!
State/province [91]
0
0
Thessaloniki
Query!
Country [92]
0
0
India
Query!
State/province [92]
0
0
Andhra Pradesh
Query!
Country [93]
0
0
India
Query!
State/province [93]
0
0
Karnataka
Query!
Country [94]
0
0
India
Query!
State/province [94]
0
0
Kerala
Query!
Country [95]
0
0
India
Query!
State/province [95]
0
0
Maharashtra
Query!
Country [96]
0
0
India
Query!
State/province [96]
0
0
West Bengal
Query!
Country [97]
0
0
India
Query!
State/province [97]
0
0
Puducherry
Query!
Country [98]
0
0
Ireland
Query!
State/province [98]
0
0
Cork
Query!
Country [99]
0
0
Ireland
Query!
State/province [99]
0
0
Dublin
Query!
Country [100]
0
0
Ireland
Query!
State/province [100]
0
0
Galway
Query!
Country [101]
0
0
Israel
Query!
State/province [101]
0
0
Northern District
Query!
Country [102]
0
0
Israel
Query!
State/province [102]
0
0
Haifa
Query!
Country [103]
0
0
Israel
Query!
State/province [103]
0
0
Jerusalem
Query!
Country [104]
0
0
Israel
Query!
State/province [104]
0
0
Tel Aviv
Query!
Country [105]
0
0
Israel
Query!
State/province [105]
0
0
Tel Litwinsky
Query!
Country [106]
0
0
Italy
Query!
State/province [106]
0
0
Lazio
Query!
Country [107]
0
0
Italy
Query!
State/province [107]
0
0
Bologna
Query!
Country [108]
0
0
Italy
Query!
State/province [108]
0
0
Catania
Query!
Country [109]
0
0
Italy
Query!
State/province [109]
0
0
Genova
Query!
Country [110]
0
0
Italy
Query!
State/province [110]
0
0
Milan
Query!
Country [111]
0
0
Italy
Query!
State/province [111]
0
0
Novara
Query!
Country [112]
0
0
Italy
Query!
State/province [112]
0
0
Pavia
Query!
Country [113]
0
0
Italy
Query!
State/province [113]
0
0
Pisa
Query!
Country [114]
0
0
Italy
Query!
State/province [114]
0
0
Reggio Calabria
Query!
Country [115]
0
0
Italy
Query!
State/province [115]
0
0
Roma
Query!
Country [116]
0
0
Italy
Query!
State/province [116]
0
0
San Giovanni Rotondo FG
Query!
Country [117]
0
0
Italy
Query!
State/province [117]
0
0
Udine
Query!
Country [118]
0
0
Japan
Query!
State/province [118]
0
0
Ehime
Query!
Country [119]
0
0
Japan
Query!
State/province [119]
0
0
Ibaraki
Query!
Country [120]
0
0
Japan
Query!
State/province [120]
0
0
Tochigi
Query!
Country [121]
0
0
Japan
Query!
State/province [121]
0
0
Tokyo
Query!
Country [122]
0
0
Japan
Query!
State/province [122]
0
0
Yamanashi
Query!
Country [123]
0
0
Japan
Query!
State/province [123]
0
0
Aomori
Query!
Country [124]
0
0
Japan
Query!
State/province [124]
0
0
Chiba
Query!
Country [125]
0
0
Japan
Query!
State/province [125]
0
0
Fukuoka
Query!
Country [126]
0
0
Japan
Query!
State/province [126]
0
0
Kamogawa
Query!
Country [127]
0
0
Japan
Query!
State/province [127]
0
0
Kyoto
Query!
Country [128]
0
0
Japan
Query!
State/province [128]
0
0
Nagoya
Query!
Country [129]
0
0
Japan
Query!
State/province [129]
0
0
Okayama
Query!
Country [130]
0
0
Japan
Query!
State/province [130]
0
0
Osaka
Query!
Country [131]
0
0
Japan
Query!
State/province [131]
0
0
Osaka-sayama
Query!
Country [132]
0
0
Japan
Query!
State/province [132]
0
0
Sapporo
Query!
Country [133]
0
0
Japan
Query!
State/province [133]
0
0
Sendai
Query!
Country [134]
0
0
Japan
Query!
State/province [134]
0
0
Shibuya-ku
Query!
Country [135]
0
0
Japan
Query!
State/province [135]
0
0
Shinagawa-ku, Tokyo
Query!
Country [136]
0
0
Japan
Query!
State/province [136]
0
0
Toyohashi
Query!
Country [137]
0
0
Mexico
Query!
State/province [137]
0
0
Jalisco
Query!
Country [138]
0
0
Netherlands
Query!
State/province [138]
0
0
South Holland
Query!
Country [139]
0
0
Netherlands
Query!
State/province [139]
0
0
Amsterdam
Query!
Country [140]
0
0
Netherlands
Query!
State/province [140]
0
0
The Hague
Query!
Country [141]
0
0
Norway
Query!
State/province [141]
0
0
Bergen
Query!
Country [142]
0
0
Norway
Query!
State/province [142]
0
0
Oslo
Query!
Country [143]
0
0
Norway
Query!
State/province [143]
0
0
Trondheim
Query!
Country [144]
0
0
Poland
Query!
State/province [144]
0
0
Podlaskie Voivodeship
Query!
Country [145]
0
0
Poland
Query!
State/province [145]
0
0
Krakow
Query!
Country [146]
0
0
Poland
Query!
State/province [146]
0
0
Nowy Sacz
Query!
Country [147]
0
0
Poland
Query!
State/province [147]
0
0
Poznan
Query!
Country [148]
0
0
Poland
Query!
State/province [148]
0
0
Warsaw
Query!
Country [149]
0
0
Poland
Query!
State/province [149]
0
0
Walbrzych
Query!
Country [150]
0
0
Portugal
Query!
State/province [150]
0
0
Coimbra
Query!
Country [151]
0
0
Portugal
Query!
State/province [151]
0
0
Lisbon
Query!
Country [152]
0
0
Portugal
Query!
State/province [152]
0
0
Porto
Query!
Country [153]
0
0
South Korea
Query!
State/province [153]
0
0
Daegu
Query!
Country [154]
0
0
South Korea
Query!
State/province [154]
0
0
Gyeonggi-do
Query!
Country [155]
0
0
South Korea
Query!
State/province [155]
0
0
Hwasun-gun
Query!
Country [156]
0
0
South Korea
Query!
State/province [156]
0
0
Seoul
Query!
Country [157]
0
0
Spain
Query!
State/province [157]
0
0
Navarre
Query!
Country [158]
0
0
Spain
Query!
State/province [158]
0
0
Barcelona
Query!
Country [159]
0
0
Spain
Query!
State/province [159]
0
0
Cáceres
Query!
Country [160]
0
0
Spain
Query!
State/province [160]
0
0
Córdoba
Query!
Country [161]
0
0
Spain
Query!
State/province [161]
0
0
Madrid
Query!
Country [162]
0
0
Spain
Query!
State/province [162]
0
0
Málaga
Query!
Country [163]
0
0
Spain
Query!
State/province [163]
0
0
Murcia
Query!
Country [164]
0
0
Spain
Query!
State/province [164]
0
0
Oviedo
Query!
Country [165]
0
0
Spain
Query!
State/province [165]
0
0
Salamanca
Query!
Country [166]
0
0
Spain
Query!
State/province [166]
0
0
Santiago de Compostela
Query!
Country [167]
0
0
Spain
Query!
State/province [167]
0
0
Valencia
Query!
Country [168]
0
0
Spain
Query!
State/province [168]
0
0
Zaragoza
Query!
Country [169]
0
0
Sweden
Query!
State/province [169]
0
0
Borås
Query!
Country [170]
0
0
Sweden
Query!
State/province [170]
0
0
Helsingborg
Query!
Country [171]
0
0
Switzerland
Query!
State/province [171]
0
0
Chur
Query!
Country [172]
0
0
Switzerland
Query!
State/province [172]
0
0
Sankt Gallen
Query!
Country [173]
0
0
Taiwan
Query!
State/province [173]
0
0
Niao-Sung Hsiang Kaohsiung County
Query!
Country [174]
0
0
Taiwan
Query!
State/province [174]
0
0
Taichung
Query!
Country [175]
0
0
Taiwan
Query!
State/province [175]
0
0
Tainan, Taiana
Query!
Country [176]
0
0
Taiwan
Query!
State/province [176]
0
0
Taipei
Query!
Country [177]
0
0
Taiwan
Query!
State/province [177]
0
0
Taipei, Zhongzheng Dist.
Query!
Country [178]
0
0
Taiwan
Query!
State/province [178]
0
0
Taoyuan
Query!
Country [179]
0
0
Turkey (Türkiye)
Query!
State/province [179]
0
0
Ankara
Query!
Country [180]
0
0
Turkey (Türkiye)
Query!
State/province [180]
0
0
Istanbul
Query!
Country [181]
0
0
Turkey (Türkiye)
Query!
State/province [181]
0
0
Izmir
Query!
Country [182]
0
0
Turkey (Türkiye)
Query!
State/province [182]
0
0
Kurupelit
Query!
Country [183]
0
0
Turkey (Türkiye)
Query!
State/province [183]
0
0
Gaziantep
Query!
Country [184]
0
0
Turkey (Türkiye)
Query!
State/province [184]
0
0
Kayseri
Query!
Country [185]
0
0
United Kingdom
Query!
State/province [185]
0
0
Nottinghamshire
Query!
Country [186]
0
0
United Kingdom
Query!
State/province [186]
0
0
Belfast Northern Ireland
Query!
Country [187]
0
0
United Kingdom
Query!
State/province [187]
0
0
Birmingham
Query!
Country [188]
0
0
United Kingdom
Query!
State/province [188]
0
0
Canterbury Kent
Query!
Country [189]
0
0
United Kingdom
Query!
State/province [189]
0
0
Lancashire Blackpool
Query!
Country [190]
0
0
United Kingdom
Query!
State/province [190]
0
0
London
Query!
Country [191]
0
0
United Kingdom
Query!
State/province [191]
0
0
Oxford
Query!
Country [192]
0
0
United Kingdom
Query!
State/province [192]
0
0
Portsmouth
Query!
Country [193]
0
0
United Kingdom
Query!
State/province [193]
0
0
Sutton
Query!
Country [194]
0
0
United Kingdom
Query!
State/province [194]
0
0
Wolverhampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Celgene
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Query!
Trial website
https://clinicaltrials.gov/study/NCT04975997
Query!
Trial related presentations / publications
Lonial S, Dimopoulos MA, Berdeja JG, Richardson PG, Quach H, Rodriguez-Otero P, Maciag P, Hong K, Amatangelo M, Chen M, van de Donk NWCJ. EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol. 2025 Jun;21(14):1761-1769. doi: 10.1080/14796694.2025.2501920. Epub 2025 May 10.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
855-907-3286
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
See Plan Description
Query!
Available to whom?
See Plan Description
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT04975997
Download to PDF